Reishi — Research Profile

Yes, reishi has a calming, GABAergic-like effect that can improve sleep quality. Cui et al. (2012) showed significant improvements in subjective sleep quality after 8 weeks of supplementation. Unlike melatonin, reishi does not induce drowsiness acutely but rather promotes overall relaxation and reduces the hyperarousal that prevents restful sleep. Taking it 1-2 hours before bed is a common approach.

For most healthy adults, daily reishi use at recommended doses (1-3g) appears safe for several months. However, rare cases of liver toxicity have been reported with concentrated reishi powders, so periodic liver function monitoring may be prudent with long-term use. People with autoimmune conditions, bleeding disorders, or those on immunosuppressants should consult a healthcare provider.

Look for: (1) fruiting body extract, not mycelium on grain; (2) dual extraction (hot water + alcohol) to capture both polysaccharides and triterpenes; (3) standardization to both beta-glucans (>20%) and triterpenes; (4) third-party testing for heavy metals. Avoid products that list "myceliated grain" or "mycelial biomass" as these are primarily grain starch with minimal mushroom compounds.

Standardized extracts are the form with actual trial support; the Cochrane cancer trials and the fitness/stress RCT both used extract preparations, not raw mushroom. Powdered reishi is the form Memorial Sloan Kettering links to hepatotoxicity. No head-to-head study has compared extract, powder, spore or tincture forms, so "best" reflects safety and trial precedent rather than a proven superiority.

Proven benefits are limited and mostly adjunctive. The Cochrane review found that adding G. lucidum to chemotherapy or radiotherapy modestly raised tumour response (RR 1.50, 95% CI 0.90–2.51) and small immune-marker increases (CD3 +3.91%, CD4 +3.05%, CD8 +2.02%) with improved quality of life, but concluded the evidence is insufficient to use it as a first-line cancer treatment. A broader systematic review of medicinal mushrooms in cancer likewise called the evidence inconclusive, and Memorial Sloan Kettering notes RCTs do not support reishi for reducing cardiovascular risk factors in type 2 diabetes.

No standardized daily dose has been established for reishi. In a double-blind trial, 500 mg and 1000 mg per day of extract were tested for 30 days, with the 1000 mg dose producing the significant fitness and mood improvements; the cancer trials pooled by Cochrane used varying extract regimens rather than a single agreed dose. Because potency differs sharply between products, dosing should follow a specific product's extract labeling rather than a universal number.

Time of day has not been directly compared for reishi. Clinical trials simply dosed it once daily over the study period without testing morning versus evening administration, so no timing has been shown to change results. Taking it with food may blunt the mild digestive side effects some users report.

Commonly reported side effects are mild: nausea, insomnia, dry mouth, constipation and vertigo per Memorial Sloan Kettering, and a systematic review of medicinal mushrooms in cancer found adverse effects were mostly grade 2 or lower (nausea, vomiting, diarrhea, muscle pain). Rare but serious harms include hepatotoxicity linked to powdered reishi, chronic diarrhea after prolonged use, and isolated reports of hypereosinophilia with liver nodules. Bleeding risk can also rise.

Yes. Memorial Sloan Kettering reports that reishi can increase bleeding risk, so it should be used cautiously with anticoagulant or antiplatelet drugs, and its immune-enhancing activity may work against immunosuppressant medications. It inhibits CYP2E1, CYP1A2 and CYP3A enzymes in vitro (potentially affecting drugs cleared by those pathways) and can theoretically interact with chemotherapy; reishi spore powder has also been reported to elevate the CA72-4 tumor marker, which may confound cancer monitoring.

Evidence is too limited to recommend reishi for any specific group as a proven therapy; its most studied use is as an add-on to conventional cancer treatment, where Cochrane found it insufficient as a stand-alone or first-line option. It should be avoided by people taking anticoagulants, antiplatelets or immunosuppressants, those approaching surgery, anyone with liver concerns given the hepatotoxicity reports, and pregnant or breastfeeding people for whom safety data are lacking.

No trial has directly established how quickly reishi acts, and the timeline depends entirely on the outcome. In a 78-person randomized trial, measurable improvements in heart rate, VO2max and grip strength emerged over 30 days of daily extract dosing, while the cancer trials pooled by Cochrane ran for weeks to months as an adjunct to chemotherapy or radiotherapy. Treat any 30-day-plus expectation as approximate rather than a validated onset window.

Long-term safety is not well established. Within the short cancer trials pooled by Cochrane, side effects were minimal (nausea, insomnia) with no significant blood or liver toxicity reported, but those trials were brief. Against that, Memorial Sloan Kettering documents fatal hepatotoxicity linked to powdered reishi and chronic diarrhea after prolonged consumption, so open-ended daily use of powdered whole-mushroom products in particular is not supported by safety data.

There is no established upper limit for reishi. The clearest safety signal is hepatotoxicity: Memorial Sloan Kettering reports liver injury, including one death, associated specifically with powdered reishi mushroom, whereas the standardized extracts used in trials were generally tolerated. Because the form matters more than a single numeric ceiling, powdered whole-mushroom preparations warrant the most caution.

The main concern is additive bleeding risk: Memorial Sloan Kettering notes reishi can increase bleeding, so pairing it with fish oil, ginkgo, high-dose vitamin E or other supplements that affect clotting is inadvisable without medical oversight. Reishi also inhibited CYP2E1, CYP1A2 and CYP3A enzymes in laboratory studies, which could in theory alter how other supplements or drugs are metabolized. No supplement combination has been shown to improve reishi's benefits.

Favor a characterized extract over raw powdered mushroom, since the fatal hepatotoxicity flagged by Memorial Sloan Kettering was tied to powdered reishi while trials used extracts. There is no agreed potency standard, but products are commonly standardized to polysaccharides and/or triterpenes, so a label stating those fractions is more informative than "mushroom powder" alone. Because mushrooms concentrate contaminants, third-party testing for heavy metals is worth checking.